Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) were up 0.7% on Wednesday . The company traded as high as $29.88 and last traded at $28.81. Approximately 549,604 shares changed hands during trading, an increase of 997% from the average daily volume of 50,104 shares. The stock had previously closed at $28.60.
Neoleukin Therapeutics Stock Up 3.5%
The company has a market cap of $272.54 million, a P/E ratio of -9.32 and a beta of 1.11. The business has a 50-day moving average price of $26.40 and a two-hundred day moving average price of $22.01.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.
The company’s lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses.
Read More
- Five stocks we like better than Neoleukin Therapeutics
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
